Reports for APOTEX INC
Company Name
APOTEX INC
Totals |
||
Shortage reports |
3546 |
|
| Actual shortage: | 240 (7%) | |
| Anticipated shortage: | 3 (0%) | |
| Avoided shortage: | 11 (0%) | |
| Resolved: | 3292 (93%) | |
Discontinuation Reports |
366 |
|
| To be discontinued: | 24 (7%) | |
| Discontinued: | 342 (93%) | |
| Reversed: | 0 (0%) | |
Late reports |
143 (4%) |
|
Overdue reports |
32 (12%) |
|
Shortage reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2021-10-01 | 2022-01-24 | 146503 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2022-01-14 | 2022-02-03 | 152758 |
| APO-DARIFENACIN | 15MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-01 | 2024-07-05 | 212368 |
| APO-DARIFENACIN | 7.5MG | TABLET (EXTENDED-RELEASE) | Resolved | 2023-12-15 | 2024-10-11 | 213547 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2020-06-04 | 2020-06-26 | 116530 |
| APO-DARUNAVIR | 600MG | TABLET | Resolved | 2024-06-06 | 2024-10-07 | 229752 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2020-10-14 | 2020-11-02 | 126277 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2021-01-08 | 2021-03-17 | 131145 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2021-01-29 | 2021-03-25 | 132715 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-02-19 | 2021-03-04 | 134430 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2021-09-24 | 2021-11-19 | 146154 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-06-17 | 2022-07-19 | 162910 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2022-07-19 | 2022-08-12 | 164882 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2022-10-21 | 2022-12-17 | 172360 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2022-11-20 | 2022-12-17 | 175315 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2022-12-05 | 2023-03-16 | 177126 |
| APO-DASATINIB | 70MG | TABLET | Resolved | 2024-04-19 | 2024-06-21 | 225776 |
| APO-DASATINIB | 100MG | TABLET | Resolved | 2024-09-12 | 2024-09-20 | 237354 |
| APO-DASATINIB | 50MG | TABLET | Resolved | 2025-08-08 | 2025-10-10 | 264827 |
| APO-DASATINIB | 20MG | TABLET | Resolved | 2025-08-14 | 2025-11-21 | 265269 |
Discontinuation reports
| Brand name | Strength | Dosage | Status | Date Created | Date Updated | Reports |
|---|---|---|---|---|---|---|
| APO-TIMOP | 0.5% | SOLUTION | Discontinued | 2019-01-03 | 2019-01-03 | 70894 |
| APO-TIMOP GEL | Discontinued | 2019-01-03 | 2019-01-03 | 71020 | ||
| APO-TIMOP | Discontinued | 2019-01-02 | 2019-01-02 | 70818 | ||
| APO-TOLTERODINE | 1MG | TABLET | Discontinued | 2018-09-08 | 2019-01-17 | 60822 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2018-11-09 | 60825 |
| APO-TOLTERODINE | 2MG | TABLET | Discontinued | 2018-09-08 | 2019-06-12 | 60828 |
| APO-TRAZODONE TABLETS 100MG | 100MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60831 |
| APO-TRAZODONE TABLETS 50MG | 50MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60834 |
| APO-VALACYCLOVIR | 500MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60840 |
| APO-VALGANCICLOVIR | 450MG | TABLET | Discontinued | 2018-09-08 | 2018-09-15 | 60843 |
| APO-VALPROIC ACID ORAL SOLUTION | 250MG | SOLUTION | Discontinued | 2023-09-26 | 2023-11-02 | 205310 |
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71029 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71032 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71035 | ||
| APO-VALSARTAN | Discontinued | 2019-01-03 | 2019-01-03 | 71038 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71044 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71048 | ||
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71051 | ||
| APO-VALSARTAN/HCTZ | 12.5MG 160MG | TABLET | Discontinued | 2019-01-03 | 2019-01-03 | 71054 |
| APO-VALSARTAN/HCTZ | Discontinued | 2019-01-03 | 2019-01-03 | 71057 |